JP5931724B2 - ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物 - Google Patents

ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物 Download PDF

Info

Publication number
JP5931724B2
JP5931724B2 JP2012518575A JP2012518575A JP5931724B2 JP 5931724 B2 JP5931724 B2 JP 5931724B2 JP 2012518575 A JP2012518575 A JP 2012518575A JP 2012518575 A JP2012518575 A JP 2012518575A JP 5931724 B2 JP5931724 B2 JP 5931724B2
Authority
JP
Japan
Prior art keywords
pneumoniae
seq
polypeptide
vaccine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012518575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532134A5 (https=
JP2012532134A (ja
Inventor
トッド ギーラーン，
トッド ギーラーン，
リチャード マレイ，
リチャード マレイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2012532134A publication Critical patent/JP2012532134A/ja
Publication of JP2012532134A5 publication Critical patent/JP2012532134A5/ja
Application granted granted Critical
Publication of JP5931724B2 publication Critical patent/JP5931724B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2012518575A 2009-06-29 2010-06-29 ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物 Expired - Fee Related JP5931724B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22154109P 2009-06-29 2009-06-29
US61/221,541 2009-06-29
US24061609P 2009-09-08 2009-09-08
US24059809P 2009-09-08 2009-09-08
US61/240,616 2009-09-08
US61/240,598 2009-09-08
US31626710P 2010-03-22 2010-03-22
US61/316,267 2010-03-22
PCT/US2010/040406 WO2011008548A1 (en) 2009-06-29 2010-06-29 Vaccines and compositions against streptococcus pneumoniae

Publications (3)

Publication Number Publication Date
JP2012532134A JP2012532134A (ja) 2012-12-13
JP2012532134A5 JP2012532134A5 (https=) 2014-04-03
JP5931724B2 true JP5931724B2 (ja) 2016-06-08

Family

ID=43449681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518575A Expired - Fee Related JP5931724B2 (ja) 2009-06-29 2010-06-29 ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物

Country Status (15)

Country Link
US (2) US10105412B2 (https=)
EP (1) EP2448592B1 (https=)
JP (1) JP5931724B2 (https=)
KR (1) KR101748453B1 (https=)
CN (2) CN107126557A (https=)
AU (1) AU2010273708B2 (https=)
BR (1) BRPI1011919A2 (https=)
CA (1) CA2803061A1 (https=)
IL (1) IL217166A0 (https=)
IN (1) IN2012DN00791A (https=)
MX (1) MX2012000158A (https=)
NZ (1) NZ597858A (https=)
RU (1) RU2580299C2 (https=)
SG (2) SG177402A1 (https=)
WO (1) WO2011008548A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580299C2 (ru) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Вакцины и композиции, направленные против streptococcus pneumoniae
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
UA112067C2 (uk) * 2010-12-21 2016-07-25 Макс-Планк-Гезельшафт Цур Фордерунг Дер Віссеншафтен Ай.Еф. Визначення ефективності антимікобактеріальної вакцинації
WO2012100233A1 (en) * 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
TW201249824A (en) 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
CA2897020A1 (en) * 2012-01-20 2013-07-25 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
US10881729B2 (en) 2014-04-18 2021-01-05 Children's Medical Center Corporation Vaccine adjuvant compositions
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
MX2020005584A (es) 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
RU2728938C1 (ru) * 2020-05-06 2020-08-03 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Применение даларгина для производства лекарственных средств профилактики пневмонии
WO2022013160A1 (en) 2020-07-16 2022-01-20 Henriques Normark Birgitta Streptococcal vaccines
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
JP4469026B2 (ja) * 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1998059071A1 (en) 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Lyme disease vaccines
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5882885A (en) * 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) * 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CN1318103A (zh) 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
JP2003501110A (ja) 1999-06-10 2003-01-14 メディミューン，インコーポレーテッド 肺炎連鎖球菌タンパク質とワクチン
US6887480B1 (en) * 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
WO2001048208A2 (en) * 1999-12-23 2001-07-05 Vmax Limited Streptococcus pyogenes virulence genes and proteins and their use
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2881568C (en) * 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2277897A1 (en) * 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP2275122A3 (en) * 2002-04-02 2011-05-18 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
WO2004020609A2 (en) 2002-08-30 2004-03-11 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
EP2311988A1 (en) * 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
GB0318688D0 (en) * 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
JP2008525033A (ja) 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
WO2006084467A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
AU2007225238A1 (en) * 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
CA2687375C (en) 2007-05-18 2017-08-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primers and probes for the detection of streptococcus pneumoniae
US20110097360A1 (en) 2007-05-25 2011-04-28 Claudio Donati Streptococcus pneumoniae pilus antigens
WO2008150885A1 (en) * 2007-05-29 2008-12-11 Board Of Regents, The University Of Texas System Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009033742A2 (en) * 2007-09-14 2009-03-19 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
WO2010150242A2 (en) 2009-06-25 2010-12-29 Protea Vaccine Technologies Ltd. Immunogenic streptococcus pneumoniae peptides and peptide-multimers
RU2580299C2 (ru) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Вакцины и композиции, направленные против streptococcus pneumoniae
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (ja) * 2010-04-06 2012-10-31 株式会社日立製作所 管理方法及び管理装置
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2011141968A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
WO2012100233A1 (en) * 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae

Also Published As

Publication number Publication date
RU2580299C2 (ru) 2016-04-10
EP2448592A4 (en) 2013-04-24
US20190298795A1 (en) 2019-10-03
CA2803061A1 (en) 2011-01-20
MX2012000158A (es) 2012-06-08
CN107126557A (zh) 2017-09-05
BRPI1011919A2 (pt) 2017-09-26
US20110020386A1 (en) 2011-01-27
KR20120093141A (ko) 2012-08-22
IN2012DN00791A (https=) 2015-06-26
AU2010273708B2 (en) 2015-10-01
EP2448592B1 (en) 2020-06-17
NZ597858A (en) 2014-01-31
EP2448592A1 (en) 2012-05-09
JP2012532134A (ja) 2012-12-13
AU2010273708A1 (en) 2012-02-23
WO2011008548A8 (en) 2012-03-08
IL217166A0 (en) 2012-02-29
AU2010273708A8 (en) 2012-06-14
WO2011008548A1 (en) 2011-01-20
US10105412B2 (en) 2018-10-23
RU2011153032A (ru) 2013-08-10
KR101748453B1 (ko) 2017-06-16
SG10201403702SA (en) 2014-09-26
SG177402A1 (en) 2012-02-28
US11207375B2 (en) 2021-12-28
CN102548572A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
JP2017160238A (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae
HK1192166A (en) Vaccines and compositions against streptococcus pneumoniae
NZ614460B2 (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160427

R150 Certificate of patent or registration of utility model

Ref document number: 5931724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees